DISCO: Discharge Stewardship in Children's Hospitals

Sponsor
Children's Hospital of Philadelphia (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05826873
Collaborator
Seattle Children's Hospital (Other), Primary Children's Hospital (Other), St. Louis Children's Hospital (Other), University of Pennsylvania (Other), Agency for Healthcare Research and Quality (AHRQ) (U.S. Fed)
5,720
5
2
60.7
1144
18.9

Study Details

Study Description

Brief Summary

The goal of this interventional study is to test if a discharge stewardship bundle is effective at reducing inappropriate antibiotic prescriptions at hospital discharge for children with the three common infections: community-acquired pneumonia (CAP), urinary tract infections (UTI), and skin/soft tissue infections (SSTI). The goals of this study are:

  • To develop, locally adapt, and implement a discharge stewardship intervention across four geographically diverse children's hospitals.

  • To measure the impact of the discharge stewardship intervention on antibiotic prescribing and patient outcome for three common pediatric infections.

Families who are enrolled in the study will be asked to:
  • complete a one question wellness track on days 3, 7, and 21 after hospital discharge

  • complete a brief survey on days 7 and 21 after hospital discharge

The study team will conduct interviews with the hospitalists at each of the four participating hospitals to create a "discharge stewardship" bundle. Once the bundle intervention is implemented, the hospitalists will be asked to follow prescribing guidelines for CAP, UTI, and SSTI. They will receive regular group-level feedback reports to show how well they follow the guidelines and motivate the hospitalists to follow the guidelines better.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Discharge antibiotic stewardship intervention
N/A

Detailed Description

Pediatric antibiotic stewardship programs (ASPs) in hospital and outpatient settings optimize the use of antibiotics to improve clinical outcomes, decrease adverse drug events, and reduce the emergence of antibiotic resistant bacteria. However, stewardship for patients at the transition from hospital discharge to home, or "discharge stewardship," is an unmet need for several reasons. First, few pediatric stewardship programs perform discharge stewardship. Second, approximately 30% of pediatric patients receive antibiotics at hospital discharge. Third, the majority of antibiotic days prescribed for hospitalized patients occur after discharge. Fourth, up to half of discharge antibiotic prescriptions are suboptimal, which includes choosing the wrong drug, dose, route, or duration of therapy.

This project will use an implementation science framework to develop, implement, and test the effectiveness of a multifaceted discharge stewardship intervention for hospitalized children with the three most common indications for antibiotic prescribing in hospitalized children - community acquired pneumonia (CAP), urinary tract infections (UTI), and skin/soft tissue infections (SSTI) - at four children's hospitals to establish a foundation for future expansion to additional target populations. Antibiotic choice, dose, route, and duration of therapy will be addressed.

Aim 1 is to develop, locally adapt, and implement a discharge stewardship intervention across the four participating sites. The integrated Promoting Action on Research Implementation in Health Services (i-PARIHS) framework will guide a rapid formative evaluation to identify contextual factors likely to facilitate or hinder the implementation of a discharge stewardship intervention at each site. Based on these results, local facilitators will work to develop and implement a discharge stewardship intervention comprised of consensus driven clinical prescribing guidelines for CAP, UTI, and SSTI plus quarterly feedback of prescribing data based on these guidelines. Aim 2 is to measure the impact of the discharge stewardship intervention on antibiotic prescribing (the primary outcome) and patient-centered balancing measures (post-discharge treatment failure and adverse events).

This project will form the foundation for future dissemination of discharge stewardship to a broader array of patient populations. Investigators on this proposal form the leadership of the Sharing Antimicrobial Reports for Pediatric Stewardship (SHARPS) Collaborative, a network comprised of more than 60 children's hospitals across North America that is uniquely positioned to adopt antimicrobial stewardship interventions designed to target prescribing at hospital discharge.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
5720 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
Mixed methods implementation science study with a multicenter, quasi-experimental interrupted time-series design.Mixed methods implementation science study with a multicenter, quasi-experimental interrupted time-series design.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Implementing a Discharge Stewardship Bundle to Improve Antibiotic Use at Transition From Hospital to Home
Actual Study Start Date :
Jun 10, 2020
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jul 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Pediatric Hospitalists

Prescribing physicians and hospital employees will be recruited during regularly held staff meetings prior to the data collection period. The study team will briefly introduce the study aims and methods and let the hospitalists know that the study team will be emailing them separately to ask permission for Dr. Szymczak to shadow them. Only those who have agreed will participate in the ethnographic observations. For the interviews and surveys, the study team will recruit respondents via contact made during ethnographic observations. The study team will also utilize a snowball approach by asking respondents if they know of any other staff who might be interested in participating in an interview. Approximately 120 clinicians will participate in the interviews and surveys.

Behavioral: Discharge antibiotic stewardship intervention
Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.

No Intervention: Families of hospitalized children

Families of children who were hospitalized at one of the four participating sites will be approached for consent to participate in the study. Families who consent will complete 2 brief REDCap surveys and a wellness tracker after their child is discharged from the hospital.

Outcome Measures

Primary Outcome Measures

  1. Rate of suboptimal prescribing [up to 3 years]

    The primary objective of this study is to determine the impact of a discharge stewardship intervention on antibiotic prescribing and patient outcomes for three common pediatric infection after developing and implementing the intervention across four geographically diverse children's hospitals. Impact will be measured by the rate of suboptimal prescribing (drug, dose, route, and duration) for CAP, UTI, and SSTI across the four hospitals. Suboptimal prescribing will be measured using data collected from the electronic health record. The discharge prescription data (choice and duration) will be compared to the recommended guidelines to determine if the discharge prescription was on or off guideline.

Secondary Outcome Measures

  1. Impact of the discharge stewardship intervention on post-discharge treatment failure [up to 3 years]

    Using a quasi-experimental design, the study team will assess the rate and trajectory of post-discharge treatment failure for CAP, UTI, and SSTI via patient report (post-discharge REDCap surveys)

  2. Impact of the discharge stewardship intervention on adverse drug events [up to 3 years]

    Using a quasi-experimental design, the study team will assess the rate and trajectory of adverse drug events for CAP, UTI, and SSTI via patient report (post-discharge REDCap surveys)

Eligibility Criteria

Criteria

Ages Eligible for Study:
28 Days to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Clinician Inclusion Criteria

  1. 18 year old

  2. Employed by the hospital as an attending physician, advanced practice provider, resident trainee or other clinical stakeholder (e.g. pharmacist, infectious diseases attending)

Clinician Exclusion Criteria

  1. <18 years old

  2. Not employed by the hospital

Patient Inclusion Criteria

  1. Subjects less than 18 years

  2. Diagnosed with either uncomplicated community acquired pneumonia, urinary tract infections, skin/soft tissue infections

  3. Admitted and discharged from study site

Patient Exclusion Criteria

  1. Subjects >18 years of age

  2. Hospital length of stay >7 days

  3. Requiring intensive care unit level of care

Parent Inclusion Criteria 1. Parent of eligible child

Parent Exclusion Criteria

  1. Parent of ineligible child

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. Louis Children's Hospital Saint Louis Missouri United States 63110
2 Children's Hospital of Philadelphia Philadelphia Pennsylvania United States 19104
3 University of Pennsylvania Philadelphia Pennsylvania United States 19104
4 Primary Children's Hospital Salt Lake City Utah United States 84113
5 Seattle Children's Hospital Seattle Washington United States 98105

Sponsors and Collaborators

  • Children's Hospital of Philadelphia
  • Seattle Children's Hospital
  • Primary Children's Hospital
  • St. Louis Children's Hospital
  • University of Pennsylvania
  • Agency for Healthcare Research and Quality (AHRQ)

Investigators

  • Principal Investigator: Jeffrey S Gerber, MD, PhD, Associate Professor, Pediatrics

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT05826873
Other Study ID Numbers:
  • 20-017269
  • R01HS027428-01
First Posted:
Apr 24, 2023
Last Update Posted:
Apr 24, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Children's Hospital of Philadelphia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 24, 2023